Table 1.

Characteristics of randomized clinical trials, comparing FDC with SD regimens for treatment of TB, that were included in the systematic review.

Study	No. of patients	Setting	Follow-up (mo)	Eligibility criteria	Study treatments, initial phase (2 mo)a	Jadad scale
Su, 200214	105	Taiwan	6	18+ yr with active pulmonary TB confirmed by smear or culture and no history of previous treatment for TB	FDC = INH 50 mg + RIF 120 mg + PZA 250 mg + EMB 1200 mg; SD = INH 300 mg + RIF 450 mg + PZA 150 mg + EMB 120 mg	2
Gravendeel et al., 200323	360	Indonesia	36	Sputum positive, weight of 33–50 kg, and provided written consent for participation	FDC = INH 75 mg + RIF 150 mg + PZA 400 mg + EMB 275 mg; SD = INH 300 mg + RIF 450 mg + PZA 500 mg + EMB 250 mg	2
Zaka et al., 200825	293	Pakistan	6	15–55 yr, sputum positive, no kidney, liver or heart disease, and not pregnant	Group A (FDC) = INH 75 mg + RIF 120 mg + PZA 350 mg + EMB 250 mg; Group B (FDC) = INH 60 mg + RIF 120 mg + PZA 300 mg + EMB 225 mg; Group C (SD) = INH 100 mg + RMP 450 mg and 150 mg + PZA 500 mg	3
Bartacek et al., 200922	1159	Egypt, India, Pakistan, Philippines, and Thailand	21	15+ yr, ≥2 positive sputum samples or 1 positive sputum sample and a chest X-ray, and received treatment for TB for ≤1 mo	FDC = INH 75 mg + RIF 150 mg + PZA 400 mg + EMB 275 mg; SD = INH 75 mg + RIF 150 mg + PZA 400 mg + EMB 275 mg	3
Lienhardt et al., 201124	1585	Africa, Asia, and Latin America	30	New diagnosis of TB confirmed by sputum smear-positive, received treatment for TB for ≤4 wk, fixed address, agreed to receive visitors, and provided written informed consent	FDC = INH 75 mg + RIF 150 mg + PZA 400 mg + EMB 275 mg; SD = INH 100 mg + RIF 150 mg + PZA 400 mg + EMB 400 mg	3

EMB, ethambutol; FDC, fixed-dose combination; INH, isoniazid; PZA, pirazinomide; RIF, rifampin; SD, single dose; TB, tuberculosis.

^aDoses were administered on the basis of body weight according to WHO and The European Union recommendations.